Preserving Muscle on GLP-1 While Losing Weight

When people talk about losing weight, they almost always mean losing fat. The body does not make that distinction. When you take in less energy than you spend, the weight that comes off is a mixture — fat, yes, but also water, glycogen, and a portion of lean tissue, including skeletal muscle. This is true of every form of substantial weight loss ever measured, from very-low-calorie diets to bariatric surgery to the newer GLP-1 medications. The question is never whether some lean mass is lost. It is how much, and how much of that loss can be prevented.

That question has taken on new urgency as GLP-1 receptor agonists have made large, rapid weight loss achievable for far more people than before. The medications work well — well enough that the average participant in the major trials lost between a seventh and a fifth of their body weight. But fast loss of a lot of weight is exactly the scenario in which lean mass is most at risk, and so the issue of muscle preservation has moved from a niche concern of physique athletes to a mainstream clinical conversation. This piece sets out what is known, what is uncertain, and what the evidence suggests actually helps.

Why losing weight costs lean mass

The body does not hold a vote on which tissue to surrender during an energy shortage. When intake falls below expenditure, it draws on stored energy from several sources at once. Fat is the largest and most expendable store, and most of the loss does come from fat. But muscle protein is also catabolised for fuel and for the amino acids the body needs, particularly early in a deficit and particularly when protein intake is low or resistance demands on the muscle are absent. A muscle that is neither being fed adequate protein nor being asked to do meaningful work is, from the body's accounting perspective, expensive tissue that can be partly liquidated.

As a rough rule of thumb drawn from the dieting literature, something on the order of a quarter of the weight lost during an unsupported energy deficit comes from fat-free mass rather than fat — though this proportion varies widely with the rate of loss, baseline body composition, age, protein intake, and physical activity. The faster and steeper the deficit, and the more sedentary and protein-poor the approach, the larger the lean-mass share tends to be. Slower loss, adequate protein, and resistance training push the ratio back toward fat. None of this is specific to medication; it is the basic physiology of negative energy balance, and it is why the quality of weight loss, not just the quantity, has become a central theme in obesity medicine. The broader picture of how the body defends its weight and metabolism is laid out in the metabolism pillar.

Why muscle is worth protecting

Two arguments make muscle preservation matter, and they are worth separating because they are often blurred together.

The first is metabolic. Fat-free mass is the dominant determinant of resting energy expenditure — the single biggest predictor of how many calories a body burns at rest. Lose lean tissue and you lower your resting metabolic rate, which makes the maintenance phase of weight management harder. The effect is sometimes overstated in popular writing: skeletal muscle at rest burns only around 13 to 15 kcal per kilogram per day, so the direct calorie cost of a few kilograms of lost muscle is modest, perhaps a few dozen calories. But this direct effect compounds with the broader metabolic adaptation that follows weight loss. Leibel and colleagues, in their landmark 1995 study at Columbia, showed that after a 10% weight loss, resting energy expenditure falls by more than the change in body size alone predicts — and Rosenbaum's 2010 synthesis of that work found the adaptation does not readily dissipate with time. Losing muscle on top of this adaptive drop deepens an already unfavourable metabolic picture.

The second argument, and arguably the more important one, is functional. Muscle is not only a metabolic organ; it is the tissue that lets you stand from a chair, climb stairs, carry shopping, and keep your balance. It is the principal site of glucose disposal, so it matters for insulin sensitivity and blood-sugar control. And it is the buffer against frailty in later life. Pontzer's large 2021 analysis of energy expenditure across the human life course, pooling doubly-labelled water data from thousands of people, helped clarify that much of the metabolic slowdown people attribute to aging is in fact a body-composition story — the progressive loss of lean mass, not a slowing of metabolism per kilogram of tissue. Entering older age with more muscle, and losing as little of it as possible during any deliberate weight loss, is one of the better-evidenced ways to protect long-term function. For older adults especially, the goal is to lose fat while defending the lean mass that underwrites independence.

Is weight loss on a GLP-1 any different?

This is where honesty about the evidence matters most, because the topic has generated more heat than the data currently support.

The starting point is that the GLP-1 trials were not designed primarily to measure body composition. The headline results describe total weight. In Wilding and colleagues' STEP 1 trial (2021), semaglutide produced a mean loss of about 15% of body weight over 68 weeks; in Jastreboff and colleagues' SURMOUNT-1 trial (2022), the highest tirzepatide dose produced about 21% over 72 weeks. These are large losses, and any loss of that magnitude, achieved relatively quickly, will include a meaningful amount of lean tissue. Sub-studies using imaging have estimated that lean mass accounts for a substantial share of the total — figures in the region of a quarter to 40% of weight lost have been reported — which sounds alarming until you note that this is broadly in line with what is seen in other forms of comparable weight loss, including diet and surgery.

That is the key interpretive point, and it has shifted over the past two years. Early commentary worried that GLP-1 medications might cause disproportionate muscle loss. The more recent reading, informed by quantitative-MRI work such as that of Linge and colleagues (2024) characterising body composition in GLP-1-treated patients, is more measured: muscle loss does occur, often at proportions similar to other modalities, and the more pressing questions are about muscle quality and distribution, which are still being clarified. A reasonable summary of the current state is that the lean-mass loss on these medications is a feature of rapid weight loss in general, not a unique toxicity of the drug class — and that it appears responsive to the same behavioural levers that protect lean mass during any weight loss.

There is also a plausible mechanism by which the drugs could make matters worse if intake is left unmanaged: they reduce appetite, and when appetite falls, protein is frequently the macronutrient that gets squeezed first. A person eating substantially less without deliberately prioritising protein is in precisely the nutritional state that accelerates lean-mass loss. So the medication does not create a new problem so much as intensify an old one — which is good news, because the countermeasures are well established. A practical guide to eating in this state is set out in what to eat on a GLP-1.

The levers that actually help

Three interventions have the best evidence for shifting weight loss toward fat and away from muscle. They are not exotic, and they work together rather than in isolation.

Adequate protein

Protein is the raw material for muscle maintenance, and during an energy deficit the requirement rises rather than falls. Phillips and colleagues' 2016 review of protein requirements beyond the standard RDA concluded that intakes in the region of 1.6 to 2.4 g per kilogram of body weight per day — well above the 0.8 g/kg RDA — support the preservation of lean mass during caloric restriction. Protein also carries the highest thermic effect of any macronutrient and is the most satiating, which is convenient when total intake is constrained.

The difficulty on a GLP-1 is mechanical rather than conceptual: reduced appetite and early fullness make it genuinely hard to eat enough protein, especially from large portions of meat. The usual solution is to anchor every meal around a protein source, eat protein first, and use convenient higher-protein options to close the gap. The detailed approach is set out in the high-protein meal plan for GLP-1 users, which is built around exactly this constraint.

Daily protein target	Context
~0.8 g/kg	Standard RDA — set to prevent deficiency, not to preserve muscle during a deficit
~1.6 g/kg	Lower end of the range associated with lean-mass preservation during weight loss
~2.0–2.4 g/kg	Upper end used in restriction and physique contexts; older adults often sit higher in the range

These are general figures from the nutrition literature, not a prescription; the right target for any individual depends on body size, kidney health, and clinical context, and is a conversation to have with a clinician or dietitian.

Resistance training

If protein supplies the material, resistance training supplies the signal. Asking a muscle to produce force tells the body that the tissue is needed and should be retained. It is the single most reliable way to bias weight loss toward fat. Trexler and colleagues' 2014 review of metabolic adaptation in athletes documented that resistance training, combined with adequate protein, helps preserve lean mass and metabolic rate during restriction and contributes to recovery afterward — reframing much of what gets called "metabolic damage" as a largely reversible adaptation rather than a permanent injury.

The practical implication for someone losing weight on a GLP-1 is that the medication handles appetite while a structured strength programme handles muscle. Two to four progressive sessions a week, covering the major movement patterns, is the broad recommendation. Detailed, GLP-1-specific guidance is set out in strength training on a GLP-1, and the wider role of movement during treatment — including the cardiovascular and adherence benefits — is covered in exercising on a GLP-1. On the evidence, exercise is the most important behavioural intervention available for protecting metabolic capacity through a period of weight loss.

Pace of loss

The third lever is the one people most often ignore: how fast the weight comes off. Faster, deeper deficits tend to take a larger fraction of their toll from lean tissue, because the body reaches for amino acids more readily when the energy shortfall is severe. A more moderate rate of loss gives protein intake and resistance training time to do their protective work. This is one reason the standard titration of GLP-1 medications — starting low and increasing in steps — is helpful beyond its role in limiting nausea: it tends to produce a steadier rate of loss rather than a crash. Setting expectations around a sustainable pace, rather than the fastest possible drop on the scale, is covered in setting realistic weight-loss goals on a GLP-1.

The biology you cannot fully out-train

It would be dishonest to present muscle preservation as a problem fully solved by protein and training. The same defensive biology that drives weight regain also works against lean-mass retention. After weight loss, the body lowers energy expenditure beyond what size predicts, raises hunger, and suppresses satiety — a coordinated response documented by Sumithran and colleagues (2011), whose participants still showed dysregulated appetite hormones a full year after dieting, and by Fothergill and colleagues (2016), whose Biggest Loser follow-up found resting metabolic rate roughly 500 calories per day below prediction six years on. None of the muscle-preservation levers abolishes this. They shift the composition of the loss in a favourable direction; they do not exempt anyone from the physiology of a defended weight. The honest framing is that protein, resistance training, and a sensible pace meaningfully improve the quality of weight loss, within limits the body still sets.

It is also worth being candid about the limits of the data. The GLP-1 body-composition evidence is still maturing: many estimates come from imaging sub-studies rather than the primary trials, methods for measuring lean mass differ, and the long-term functional consequences of the muscle lost on these medications have not been followed for long. What can be said with reasonable confidence is that the lean-mass loss is real, that it is broadly comparable to other forms of rapid weight loss rather than uniquely severe, and that it responds to the same well-established countermeasures. What cannot yet be said with confidence is exactly how much of it is preventable in practice, or how it plays out over a decade. Anyone pursuing weight loss should understand both halves of that statement. The wider context — including how these medications fit into obesity treatment and what the trials do and do not establish — is covered in the GLP-1 science pillar, and related supporting articles are gathered in the GLP-1 science cluster.